Therapeutic Strategies of COVID-19: from Natural Compounds to Vaccine Trials

Abstract

Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) is a novel coronavirus that caused a global epidemic named COVID-19. This disease continues to kill thousands of people around the world. Physiopathological studies showed that different organs such as lungs, brain, kidneys, immune system, and heart are affected directly and/or indirectly by this disease. With the absence of a vaccine, several treatments have been proposed, including old antiviral drugs, synthetic pharmacophores, and natural antiviral bioactive compounds. These molecules presented promising results with specific action on the virus. Moreover, other strategies are underway, such as the use of monoclonal antibodies, cell therapy, plasma therapy, and vaccine trials. In this work, we highlight the therapeutic strategies of COVID-19 natural compounds to vaccine trials.

De Novo Drug Design of Potential Inhibitors of SARS-CoV-2 Papain-like Protease

“…Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of the Coronavirus Disease 2019 (COVID-19) [1], caused an ongoing global pandemic that claimed over 6.9 million lives to date. Moreover, several global strategies were launched to find therapeutic agents against COVID-19 [2]. For example, known drugs could be repurposed to inhibit the progression of SARS-CoV-2 and reduce patient mortality [3,4].…”